

# **Anticipated acquisition of an interest in AMT-061 by CSL Behring LLC from uniQure biopharma BV**

## **Decision on relevant merger situation**

**ME/6893/20**

1. On 24 June 2020, CSL Behring LLC (**CSL**) and uniQure biopharma BV (**uniQure**) entered into a Commercialisation and Licence Agreement, under which CSL acquires rights to develop and commercialise uniQure's pipeline treatment for Haemophilia B, AMT-061.
2. On the basis of the information currently available to it, the Competition and Markets Authority does not believe that it is or may be the case that arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation because enterprises have not ceased to be distinct.
3. The acquisition will therefore not be referred under section 33 of the Enterprise Act 2002.

**Sorcha O'Carroll**  
**Director, Mergers**  
**Competition and Markets Authority**  
**24 November 2020**